Objective: To present and analyze the characteristics of the 100 most cited articles that used cerebral angiography for clinical evaluation and intervention. Method: Two researchers independently extracted articles from multiple databases and ranked them by citation count to create the “top 100 most-cited” list. Results: The top 100 articles received a total of 115,243 citations. Twenty-one of the top 100 articles were published between 2006 and 2010. Most studied disorder was ischemic stroke ( n = 35), and cerebral angiography was used most frequently for diagnosis ( n = 88).The United States was affiliated with the highest number of articles ( n = 62), with Stroke publishing most articles ( n = 22). Public sources funded 39 articles, private sources funded 35, and 38 articles reported conflicts of interest. Thirty-six studies were randomized controlled trials, and male authors held the majority of both first ( n = 90) and senior ( n = 88) authorship positions. Conclusion: Within the scope of this study, the following features may define a typical highly cited article—a randomized controlled clinical trial conducted in the United States that studied ischemic stroke, used cerebral angiography for diagnosis, and was published relatively recently in a high-impact journal by male first and senior authors.

Background and objective: The global rise in the incidence of diabetes mellitus necessitates innovative management strategies to mitigate the severity of the disease. The mainstay of diabetes treatment is still insulin therapy, although there are drawbacks, such as the need to maintain ideal glycemic control while lowering the risk of hypoglycemia and user fatigue. The development, clinical usefulness, and constraints of insulin delivery systems are examined in this narrative review, with particular attention to sensor-augmented and closed-loop technologies. Methods: A thorough electronic database search was conducted to obtain pertinent data on major insulin delivery devices, including sensor-augmented and closed-loop systems. We studied advancements in insulin delivery systems over time and their impact on the management of diabetes mellitus. We thoroughly examined both qualitative and quantitative data to summarize our conclusions. Key content and findings: Closed-loop insulin delivery systems, which combine insulin pumps, advanced control algorithms, and continuous glucose monitoring, are the next step forward in the treatment of diabetes. These systems autonomously regulate blood glucose levels, reducing the need for user intervention. Closed-loop devices outperform sensor-augmented pump (SAP) treatment in reducing hypoglycemia, extending the time-in-range, and lowering self-management responsibilities. In order to provide real-time control, closed-loop systems dynamically modify insulin delivery in response to glucose variations by using algorithms powered by artificial intelligence. Because SAP therapy depends more on user input and may not be as successful in providing consistent glycemic control, this capability helps overcome its drawbacks. Further improving overall safety and efficacy, the closed-loop technique decreases blood glucose variability. Conclusion: The two primary developments in diabetes care are sensor-augmented and closed-loop insulin devices, which offer better glucose control and lower hypoglycemia rates compared to traditional therapies. Closed-loop insulin delivery systems seem to be a more clinically successful option for controlling diabetes mellitus than SAP therapy.